Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals
NYSE MKT | Common Stock
Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally.
It operates in two segments, Specialty Brands and Specialty Generics.
The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
It offers Acthar Gel, an injectable drug for rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform, as well as Amitiza, a product for constipation.
The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; and SLN500, a ribonucleic acid technology therapy.
It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies.
Mallinckrodt plc has collaboration with Silence Therapeutics plc.
The company was founded in 1867 and is based in Dublin, Ireland.
On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in theU. S.
Bankruptcy Court for the District of Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 4, 20 | 1.89 Decreased by -25.30% | 1.34 Increased by +41.04% |
| May 5, 20 | 1.64 Decreased by -15.46% | 1.43 Increased by +14.69% |
| Feb 25, 20 | 2.40 Increased by +10.09% | 2.06 Increased by +16.50% |
| Nov 5, 19 | 2.07 Decreased by -1.43% | 1.97 Increased by +5.08% |
| Aug 6, 19 | 2.53 Increased by +42.13% | 2.08 Increased by +21.63% |
| May 7, 19 | 1.94 Increased by +48.09% | 1.70 Increased by +14.12% |
| Feb 26, 19 | 2.18 Increased by +8.46% | 1.92 Increased by +13.54% |
| Nov 6, 18 | 2.10 Increased by +6.60% | 1.79 Increased by +17.32% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 22 | 465.40 M Decreased by -8.24% | -284.90 M Decreased by -8.04% | Decreased by -61.22% Decreased by -17.74% |
| Jun 30, 22 | 383.70 M Decreased by -29.78% | -193.50 M Decreased by -82.89% | Decreased by -50.43% Decreased by -160.44% |
| Mar 31, 22 | 490.90 M Decreased by -12.03% | -119.60 M Increased by +16.89% | Decreased by -24.36% Increased by +5.53% |
| Dec 31, 21 | 597.20 M Decreased by -14.48% | -204.00 M Decreased by -206.47% | Decreased by -34.16% Decreased by -224.50% |
| Sep 30, 21 | 507.20 M Decreased by -27.64% | -263.70 M Increased by +71.74% | Decreased by -51.99% Increased by +60.95% |
| Jun 30, 21 | 546.40 M Decreased by -17.93% | -105.80 M Decreased by -110.76% | Decreased by -19.36% Decreased by -156.81% |
| Mar 31, 21 | 558.00 M Decreased by -30.67% | -143.90 M Increased by +87.56% | Decreased by -25.79% Increased by +82.06% |
| Sep 30, 20 | 698.30 M Decreased by -6.10% | 191.60 M Increased by +17.52 K% | Increased by +27.44% Increased by +18.65 K% |